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Abstract: Photosensitization by drugs is a problem of increasing importance in modern life.
This phenomenon occurs when a chemical substance in the skin is exposed to sunlight.
Photosensitizing drugs are reported to cause severe skin dermatitis, and indeed, it is generally advised
to avoid sunbathing and to apply sunscreen. In this context, the nonsteroidal anti-inflammatory
drug (NSAID) diclofenac is a photosensitive drug, especially when administered in topical form.
In this work, efforts have been made to design and study an innovative pro-drug/pro-filter system
containing diclofenac and the UVA filter avobenzone in order to develop a safer use of this topical
drug. The design is based on the presence of a well-established photoremovable phenacyl group
in the avobenzone structure. Steady-state photolysis of the dyad in hydrogen-donor solvents,
monitored by UV-Vis spectrophotometry and HPLC, confirms the simultaneous photorelease of
diclofenac and avobenzone. Laser flash photolysis and phosphorescence emission experiments
allow us to gain insight into the photoactive triplet excited-state properties of the dyad. Finally,
it is shown that avobenzone provides partial photoprotection to diclofenac from photocyclization to
carbazole derivatives.
Keywords: photochemistry; photolabile protecting group; photoprotection; phototoxicity
1. Introduction
The harmful effect of sunlight is becoming a public health concern due to the increased incidence of
skin cancer [1–3]. This has been associated with sun exposure in connection with sun-seeking behavior,
tanning fashion, and outdoor activities. Fortunately, the main UV-component of sunlight—UVA,
which includes wavelengths ranging from 320 to 400 nm—is hardly absorbed by biomolecules.
However, UVA is an important factor in the process of chemical photosensitization, during which light
does not interact directly with biological components, but is absorbed by endogenous or exogenous
compounds that can act as photodamaging agents [4–7].
Topical drugs are of special relevancy as they are applied to the skin’s surface, and thus, they are
directly exposed to sunlight irradiation without suffering the filtering effect provided by the dermis and
epidermis. In this context, nonsteroidal anti-inflammatory drugs (NSAIDs) contained in topical pain
relievers are of widespread use for the treatment of musculoskeletal disorders. Topical formulations
containing diclofenac (DCF) as the pharmacologically active agent are among the most commonly
utilized because they are available in many countries without the need for a medical prescription.
The topical form generally exhibits a better safety profile than the systemic form, as it reduces the
diffusion of the drug in the organism, thus avoiding the appearance of the most common side
effects. However, direct application of the drug is not always harmless and is at the origin of skin
photosensitivity. In this context, several cases of photoallergic contact dermatitis have been reported
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for DCF as a topical pain reliever [8–13], but also when it is the active component in the treatment of
actinic keratosis [14].
Photochemical studies have revealed that diclofenac is not stable under irradiation, and it
undergoes a photocyclization process that gives rise to a primary photoproduct that is a chlorocarbazole
derivative (CBZCl), which in turn photodechlorinates to yield the corresponding carbazole (CBZ),
as illustrated in Scheme 1 [15–17]. In vitro experiments have shown that CBZCl is the main contributor
to lipid peroxidation through a radical-mediated mechanism, while DCF participates to a lesser
extent [16]. This difference may be exaggerated by the fact that carbazoles exhibit higher UVA
absorption than diphenylamine derivatives, and thus are more prone to be excited by sunlight radiation
that causes them to reach their photoreactive states [15].
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Indeed, the medical leaflet for diclofenac gel contains explicit warnings regarding its
photoreactivity, which advise th pati nt to minimize or avoid natural or artificial sun exposure of
treated areas. Recent tudies have sh wn that the photost bility of DCF can be e hanced by improving
its topical formulation and by including solar filters [18,19]. In this context, we have designed a new
pro-drug/pro-filter compound that contains another photosensitizing NSAID, namely ketoprofen,
and its complementary UVA filter avobenzone [20]. This dyad takes ad ntage of the diketo
tautomer of avobenzone (AB, 4-tert-butyl-4′-methoxydibenzoylmethane) s a phe acyl-like photolabile
protecting group that is able to photorelease carboxylic acid derivatives [21–24]. Avobenzone is
widely used as a UVA filter in sunscreen and cosmetic preparations. In solution, as with most of
dibenzoylmethane derivatives, the tautomeric equilibrium is displaced towards the keto-enol form,
which is respo sible for its high UVA absorption. Thus, the concept is bas on the fact that the dyad
is cleaved through irradiation, photoreleasing the phototoxic drug and its protective UVA shield.
In this work, a similar approach has been envisaged for DCF. This time the diketo form present
in the photoactivatable dyad should afford protection to DCF, while th keto-enol tautomer overlaps
the UVA-absorption region of the carbazole-like photoproducts. Thus, the designed dyad AB-DCF,
which contains the diclofenac anchored to the α-position of the AB diketo groups (Scheme 2), should
release the active drug and its associated UVA-filter AB after being exposed to simulated sunlight (SSL)
irradiation. This possibility has been checked by examining the progress of the photorelease by means
of UV-Vis absorption, fluorescence emission, and HPLC. In addition, phosphorescence emission and
laser flash photolysis experiments have also been performed to gain more insight into the photoactive
triplet excited state of the dyad.Molecules 2018, 23, x FOR PEER REVIEW  3 of 11 
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2. Results
2.1. Synthesis
The synthesis of the dyad AB-DCF was performed in two steps (Scheme 2) [20].
Briefly, the α-bromo avobenzone derivative was first obtained under solvent-free conditions
using N-bromosuccinimide as the brominating agent, following the described procedure [25].
Then, the resulting product was reacted with diclofenac cesium salt to afford the desired dyad AB-DCF
as an enantiomeric mixture. The NMR spectra (1H, 13C, COSY, and HSQC) showed that the avobenzone
moiety was present under its diketo form. Indeed, the characteristic proton signal at 6.75 ppm of
the “chelated” enol form was shifted to 6.94 ppm (see Supplementary Materials). This assignment
was confirmed by 2D NMR spectroscopy showing that this 6.94 ppm proton correlated with the
α-dicarbonyl carbon at 81.2 ppm (see Supplementary Materials).
Accordingly, the strong absorption of the avobenzone in its “chelated” enol form, with maximum
absorption at ca. 340–350 nm, was not detected in the UV-Vis absorption spectrum of AB-DCF
(Figure 1). Instead, a peak centered at 275 nm, which accounted for the absorption of the diclofenac
moiety together with that of the diketo tautomer of the avobenzone part, was observed together with
a shoulder that almost reached 390 nm. The presence of this UVA-absorbing portion was of paramount
importance in order to achieve a sunlight-triggered photorelease of the drug and the filter.
Molecules 2018, 23, x FOR PEER REVIEW  3 of 11 
 
 
Scheme 2. Synthetic scheme of the diclofenac/avobenzone photoactivatable dyad (AB–DCF). 
2. Results 
2.1. Synthesis 
The synthesis of the dyad AB-DCF was performed in two steps (Scheme 2) [20]. Briefly, the α-
bromo avobenzone derivative was first obtained under solvent-free conditions using N-
bromosuccinimide a  the brominating agent, following the described procedure [25]. Then, the 
resulting product was reacted with diclofenac cesium salt to afford the desired dyad AB–DCF as an 
enantiomeric mixtur . The NMR spectra (1H, 13C, COSY, and HSQC) showed that the avobenzone 
moiety was present under its diketo form. Indeed, the characteristic proton signal at 6.75 ppm of the 
“chelated” enol form was shifted to 6.94 ppm (see Supplementary Materials). This assignment was 
confirmed by 2D NMR pectroscopy showing that this 6.94 ppm roton correlated with the α-
dicarbonyl carbon at 81.2 ppm (see Supplementary Mat rials). 
Accordingly, the strong absorption of the avobenzone in its ‘‘chelated’’ enol form, with 
maximum absorption at ca. 340–350 nm, was not detected in the UV-Vis absorption spectrum of AB–
DCF (Figure 1). Inste d, a peak centered at 275 nm, which accounted for the absorption of the 
diclofenac moiety together with that of the diketo tautomer of the avobenz e part, was observed 
together with a shoulder that almost reached 390 nm. The presence of this UVA-absorbing portion 
was of paramount importance in order to achieve a sunlight-triggered photorelease of the drug and 
the filter. 













Wavelength (nm)  
Figure 1. UV-Vis absorption spectra of avobenzone (AB, blue), diclofenac (DCF, green), and the dyad 
AB-DCF (red) in ethanol at ca. 1.5 × 10−5 M. 
2.2. Photorelease Experiments 
2.2.1. UV-Vis Absorption 
Steady-state photolysis of AB-DCF was performed under SSL conditions. Ethanolic solutions of 
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Figure 1. UV-Vis ab orption spectra of avobe zone (AB, blue), i lofenac (DCF, green), and the dyad
AB-DCF (red) in ethanol at ca. 1. × 10−5 M.
2.2. Photorelease Experiments
2.2.1. UV-Vis Absorption
Steady-state photolysis of AB-DCF was performed under SSL conditions. Ethanolic solutions
of the dyad (4.3 × 10−5 M) were irradiated under aerobic or anaerobic conditions. Owing to the
characteristic UV absorbance of the “chelated” avobenzone, its photorelease was easily followed by
UV-Vis absorption. Very different spectral chang s were registered for air- or nitrogen-equilibrated
solutions (Figure 2). Indeed, under deaerated conditions, the maximum absorption at 275 nm was
shifted and decreased during irradiation, while the 355 nm band increased. By contrast, under aerated
conditions, the decrease of the maximum absorption did not result in the formation of a new UVA band.
These results led us to look for a reaction medium more similar to the in vivo application conditions.
Therefore, an alternative approach was envisaged to improve air-equilibrated experiments. It was
based on using a hydrogen-donor solvent with properties such as low O2 solubility, high viscosity,
and thus, a low diffusion-controlled rate constant, which altogether was thought to favor the
photorelease of diclofenac and avobenzone (Scheme 3). Diethylene glycol (dEtGly) appeared as
Molecules 2018, 23, 673 4 of 11
a matrix of interest as it fulfilled the preceding points; moreover, it is an ingredient (co-solvent)
in topical drug or healthcare product formulations. Irradiation of an aerated solution of AB-DCF
(6.6 × 10−5 M) in dEtGly confirmed that the solvent choice was appropriate, as observed from the
absorption spectra shown in Figure 3, which exhibited the characteristic growth of the avobenzone
band at 355 nm.
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Scheme 3. Photorelease of AB and DCF from the dyad (AB-DCF).
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2.2.2. HPLC Analysis
The experiments using UV-Vis spectrophotometry gave us a first insight into the viability of
our system. However, the superposition of the absorption spectrum of DCF with that of the initial
dyad (Figure 1) did not allow a clean quantitation of the drug release. Thus, HPLC experiments were
carried out to overcome this limitation. The quantitation of the different compounds was achieved by
using authentic samples of AB-DCF, AB, and DCF for calibration. Upon SSL irradiation of AB-DCF
in deaerated EtOH, almost 60% of the dyad was consumed after 60 min, giving rise to DCF and AB
formations (Figure 4A). The same tendency, with a somewhat higher release of AB, was observed for
an aerated solution of DCF in dEtGly as shown in Figure 4B.
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2.2.3. Fluorescence Analysis
As mentioned above, the phototoxic properties of diclofenac are due to the formation of
a chlorocarbazole photoproduct CBZCl, and its subsequent photodehalogenation to CBZ. Formation
of these photoproducts can be easily followed by fluorescence emission as, in contrast with the parent
drug, they exhibit a fluorescence emission with λem at ca. 350 and 360 nm [15]. Thus, SSL irradiations
were carried out in aerated dEtGly solutions of DCF alone, DCF in the presence of AB (1:1, DCF+AB),
and AB-DCF (Figure 5). Under irradiation, the maximum absorption of the drug at 270 nm decreased
concomitantly with the increase of red-shifted bands with λmax at ca. 294, 325, and 336 nm (Figure 5A),
which is consist nt with the form tion of the carbazole-derived photoproducts [15]. Concerning
the absorption measurem nts of th equimolar mixture DCF+AB or the dyad, the UVA band of the
keto-enol f rm of AB overlapped with those of the photoproducts (Figure 5B,C), preventing them
from following their kinetics of formation. This difficulty was anticipated, as AB was expected to
provide photoprotection to the photoproducts. Fortunately, the non-fluorescent AB did not interfere
in the emission measurements, allowing us to monitor the photoproducts formation. As shown in
Figure 5A’–C’, the increased emission intensity due to the carbazole derivatives was markedly lower
for the equimolar DCF+AB mixture, as well as for the dyad AB-DCF. This is clearly illustrated in
Figure 6 by plotting of the fluorescence intensity (at λem ca. 367 nm) as a function of the irradiation time.
In summary, fluorescence monitoring of the irradiations reveals that, both in the equimolar
DCF+AB mixture and in the AB-DCF dyad, partial protection was provided by the preexisting or
nascent keto-e ol form o the filter, although form ion of the carbazole-derived phot product was
not completely prevented. The advantage of using the dyad instead of the mixture is related to the
controlled release of the active principle.
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Figure 6. Time-course formation of carbazole-derived photoproducts followed by fluorescence, 
registering the emission intensity at 347 nm (λexc = 290 nm) for aerated solutions of DCF alone (black), 
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Figure 6. Time-course formation of carbazole- erived photoproducts followed by fluorescence,
registering the e ission i te sity t (λexc = 290 nm) for aerated solutions of DCF alone
(black), the equimolar DCF+AB mixture (blue), and the AB-DCF dyad (red) in diethylene glycol.
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2.3. Time-Resolved Experiments
Laser flash photolysis was carried out to obtain information on the transient species generated
during excitation at room temperature. Thus, for N2-bubbled solutions of AB-DCF, only one species
was observed immediately after the 355 nm laser pulse (Figure 7). This species, with a lifetime (τ)
of ca. 0.4 µs, was quenched by oxygen; under air-equilibrated conditions, the determined τ was of
ca. 0.1 µs (Figure 7, inset). This transient was similar to that previously described for α-methylated AB
(AB–Me) [26] and for the dyad containing AB and ketoprofen [20] and was thus assigned to the triplet
excited state of AB-DCF. Moreover, a comparison of the lifetime in the case of the photolabile dyad
(τ of ca. 0.4 µs) and that of the α-methyl derivative of AB (τ = 0.8 µs) suggests that the triplet excited
state was the involved species in the photorelease of AB and DCF.
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Figure 7. Transient absorption spectra of the AB-DCF dyad (6.4 × 10−4 M) in ethanol under N2, from
0.1 to 0.27 µs after the 355 nm laser pulse. Inset: decays monitored at 420 nm under N2 (black) or air
(blue) and their corresponding fittings (red).
In order to obtain additional information about the triplet excited state of AB-DCF, its
phosphorescence emission spectrum was recorded at 77 K, and a broad band was observed with
a maximum at ca. 430 nm (Figure 8). Interestingly, DCF did not show any phosphorescence emission
under the same conditions, so this moiety did not contribute to the obtained spectrum of AB-DCF.
The emission of AB-DCF was somewhat red-shifted and less structured with respect to that of the
previously described phosphorescence of AB–Me, used as reference to illustrate AB in its diketo
form [26]. However, this was consistent with a change in the α-substitution—alkyl chain versus
ester moiety.
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(black) in ethanol at 77 K at the excitation wavelength λexc of ca. 284 nm. 

















Figure 8. Phosphorescence emission spectra of CF (red), the AB-DCF dyad (blue), and AB–Me (black)
in ethanol at 77 K at the excitation wavelength λexc of ca. 284 nm.
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3. Materials and Methods
3.1. Reagents and Solvents
Avobenzone, N-bromosuccinimide, sodium diclofenac salt, anhydrous dimethylformamide,
hexane, and ethyl acetate were purchased from AK Scientific (Union City, CA, USA) and Sigma-Aldrich
(St. Louis, MO, USA) and used as received. The ethanol of HPLC grade, used for the steady-state
photolysis and laser flash photolysis experiments, was from Scharlau (Barcelona, Spain), whereas the
diethylene glycol was purchased from Panreac (Barcelona, Spain).
3.2. Characterization
The 1H and 13C NMR spectra were measured by a 300 MHz instrument (Bruker, Rivas-Vaciamadrid,
Spain), and CDCl3 was used as the solvent for all the spectra. The solvent signal was taken as the
reference using a chemical shift (δ) of ca. 7.26 ppm and 77.16 ppm for 1H and 13C NMR, respectively.
Coupling constants (J) were given in Hz. The exact mass values were determined by using a Waters
ACQUITY™ XevoQToF spectrometer (Waters Corp., Cerdanyola del Vallès, Spain) connected to
the UPLC system via an electrospray ionization (ESI) interface. The ESI source was operated in
positive ionization mode with the capillary voltage at 3.0 kV (Waters Corp., Cerdanyola del Vallès,
Spain). The temperature of the source and desolvation was set at 120 ◦C and 500 ◦C, respectively.
The cone and desolvation gas flows were 10 L h−1 and 450 L h−1, respectively. All data collected
in centroid mode were acquired using Masslynx™ software (Waters Corp., Cerdanyola del Vallès,
Spain). Leucine-enkephalin was used as the lock mass, generating an [M + H]+ ion (m/z 556.2771) at
a concentration of 250 pg/mL and a flow rate of 20 µL/min to ensure accuracy during the mass analysis.
3.3. Synthesis
2-bromo-1-(4-(tert-butyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (AB-Br). Two solids, avobenzone
(AB, 1 g, 3.2 mmol) and N-bromosuccinimide (0.57 g, 3.2 mmol) were crushed under solvent-free
conditions in a mortar for 10 min. The mixture was left standing for 2 hours and then mashed each
15 min for 2 h. Then, water was added, and the solution was filtered under a vacuum. The solid was
dried and purified by flash chromatography, using hexane:ethyl acetate as an eluent (6:1, v:v). Colorless
crystals of AB-Br were obtained (0.94 g) in a 76% yield. 1H NMR (300 MHz, D2O) δ: 7.99 (d, 2H,
J = 9 Hz), 7.93 (d, 2H, J = 9 Hz), 7.46 (d, J = 6 Hz, 2H), 6.92 (d, J = 6 Hz, 2H), 6.47 (s, 1H), 3.86 (s, 3H),
1.32 ppm (s, 9H). 13C NMR (75 MHz, D2O) δ: 188.7 (CO), 187.7 (CO), 164.4 (C), 158.2 (C), 131.9 (CH),
131.3 (C), 129.3 (CH), 126.8 (C), 126.1 (CH), 114.3 (CH), 55.7 (CH3), 53.3 (CH), 35.3 (C), 31.0 ppm (CH3).
HMRS (ESI-TOF): m/z [M + H]+ calculated for C20H22O3Br: 389.0752 found: 389.0753.
1-(4-(tert-butyl)phenyl)-3-(4-methoxyphenyl)-1,3-dioxopropan-2-yl 2-(2-((2,6-dichlorophenyl)amino)
phenyl)acetate (AB-DCF). Sodium diclofenac salt (0.18 g, 0.567 mmol) was added to a solution of
AB-Br (0.2 g, 0.515 mmol) in DMF under an inert atmosphere, and it was stirred at room temperature
for 22 h. The DMF was evaporated under vacuum, and the crude product was purified by column
flash chromatography using hexane: ethyl acetate (9:1, v:v) as an eluent. The dyad AB-DCF was
obtained as a yellowish solid—an enantiomeric mixture in 50% yield. 1H NMR (300 MHz, CDCl3)
δ: 8.01 (d, J = 9 Hz, 2H), 7.96 (d, J = 6 Hz, 2H), 7.42 (d, J = 9 Hz, 2H), 7.31 (d, J = 9 Hz, 2H), 7.24 (dd,
J = 6 Hz, J = 1 Hz, 1H), 7.13 (m, 1H), 6.98 (d, J = 9 Hz, 2H), 6.94 (s, 1H), 6.86 (d, J = 9 Hz, 2H), 6.54 (dd,
J = 9Hz, J = 1 Hz, 1H), 6.46 (bs, 1H), 4.03 (s, 2H), 3.83 (s, 3H), 1.30 (s, 9H). 13C NMR (75 MHz, CDCl3) δ:
190.5 (CO), 189.2 (CO), 170.7 (COO), 164.4 (C), 158.2 (C), 143.0 (C), 138.2 (C), 132.2 (2CH), 131.8 (C),
131.2 (CH), 129.7 (2 C), 129.6 (2 CH), 128.9 (2 CH), 128.3 (CH), 127.4 (C), 125.8 (2 CH), 124.4 (C),
124.1 (CH), 122,6 (CH), 119.1 (CH), 114.1 (2 CH), 81.2 (CH, diketonic), 55.6 (CH3, –OMe), 38.2 (CH2),
35.3 (C), 31.1 (3 CH3). HMRS (ESI-TOF): m/z [M + H]+ calculated for C34H32Cl2NO5: 604.1658 found:
604.1660.
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3.4. Photophysical/Photochemical Instrumentation
3.4.1. UV-Vis Absorption
The spectra were registered on a Cary 50 spectrophotometer (Varian, Palo Alto, CA, USA) using
a quartz cuvette of 3 mL and a 1 cm optical path.
3.4.2. Fluorescence Emission
The steady-state fluorescence experiments were carried out by means of a Photon Technology
International (PTI) LPS-220B spectrofluorometer (PTI, Birmingham, NJ, USA), equipped with an Xe
lamp (75 W) and a monochromator covering the region of 200–700 nm. The excitation λexc was 290 nm
and an emission was registered from 300 to 560 nm. Irradiations were carried out in diethylene glycol
at ca. 1.7 × 10−5 M in SSL, and the reaction was monitored in the spectrofluorometer.
3.4.3. Phosphorescence Emission
The phosphorescence spectra were registered with a Photon Technology International (PTI,
TimeMaster TM/2003, Birmingham, NJ, USA) equipped with a pulsed Xenon lamp. The equipment
worked in time-resolved mode with a delay time of 500 µs. Compounds were dissolved in ethanol
solutions with an absorbance of 0.8 at the excitation wavelength of 284 nm (value determined for a 1 cm
optical path). Then, the solution was transferred to a quartz tube of 5 mm diameter, and measurements
were performed at 77 K.
3.4.4. Laser Flash Photolysis (LFP)
The experiments were run with a pulsed Nd:YAG (L52137 V LOTIS TII, Minsk, Belarus) laser
system instrument setting 355 nm as the excitation wavelength. The pulse duration was of ca. 10 ns,
and the energy was adjusted at 26 mJ pulse−1. The apparatus consisted of the pulsed laser, the Xe
lamp, a 77250 Oriel monochromator, and a photomultiplier. The output signal from a Tektronix (Les
Ulis, France) oscilloscope was transferred to a personal computer. The transient spectra were recorded
at room temperature, employing quartz cells of 1 cm optical path length. Experiments were performed
for ethanol solutions of AB-DCF (6.4 × 10−4 M) under air and N2 atmospheres.
3.4.5. Steady-State Photolysis
The simulated sunlight irradiation was performed by a Thermo Oriel Newport (A91192A)
(Newport, CA, USA) solar simulator equipped with a 1000 W Xe arc. Its output was adequately
filtered to produce a spectrum approximating natural sunlight (1.5 G air mass filter). The spectral
output was measured as ca. 100 mW/cm2. Experiments were carried out in deaerated or aerated
ethanol solutions of AB-DCF at ca. 4.3 × 10−5 M and in aerated diethylenglycol at ca. 6.6 × 10−5 M.
Finally, HPLC (Varian, Palo Alto, CA, USA) analysis was run using SSL irradiation of AB-DCF at
1.0 × 10−3 M or 9.3 × 10−4 M in deaerated ethanol or aerated diethylene glycol, respectively.
3.4.6. HPLC Analysis
The irradiation mixtures were analyzed by reversed-phase HPLC using a Varian ProStar
instrument equipped with a diode array detector covering a detection range from 200 to 400 nm.
A Mediterranea Sea C18 column (25 mm × 0.46 mm, 5 µm) (Teknokroma, Sant Cugat, Spain) was
employed with an injection volume of 10 µL (removed from the cuvette at different irradiation times).
The mobile phase was an isocratic mixture of water at pH 3 (20%) and acetonitrile (80%) at a flow rate
of 0.7 mL min−1. Different detection wavelengths were used to detect AB-DCF (λdetection = 274 nm),
DCF (λdetection = 282 nm), or AB (λdetection = 357 nm).
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4. Conclusions
In this work, the pro-drug/pro-filter concept has been checked for a covalently linked dyad
constructed from the NSAID diclofenac (DCF) and the widely used solar filter avobenzone (AB).
Exposure of the dyad (AB-DCF) to solar simulated light in diethylene glycol under aerobic conditions
led to the simultaneous release of the two components DCF and AB, demonstrating the effective
photorelease of the drug from the photocage. In addition, the nascent AB provided partial
photoprotection to DCF, which underwent photocyclization to carbazole derivatives much slower than
it did in the absence of the solar filter. Our current work is directed toward optimizing the photorelease
yield, improving photoprotection, and testing permeation capability.
Supplementary Materials: The following are available online. 1H NMR and 13C NMR spectra of AB-DCF, DEPT
and HSQC spectra of AB-DCF, and HPLC chromatograms of AB-DCF irradiated in deaerated ethanol.
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Photosensitivity to selected topical nonsteroidal anti-inflammatory drugs preparations—A review of
literature data and author’s own experience. Cent. Eur. J. Immunol. 2011, 36, 197–203.
11. Przybilla, B.; Ring, J.; Schwab, U.; Galosi, A.; Dorn, M.; Braun-Falco, O. Photosensibilisierende Eigenschaften
nichtsteroidaler Antirheumatika im Photopatch-Test. Hautarzt 1987, 38, 18–25. [PubMed]
12. Monteiro, A.F.; Rato, M.; Martins, C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions.
Clin. Dermatol. 2016, 34, 571–581. [CrossRef] [PubMed]
13. Akat, P.B. Severe photosensitivity reaction induced by topical diclofenac. Indian J. Pharmacol. 2013, 45,
408–409. [CrossRef] [PubMed]
14. Kowalzick, L.; Ziegler, H. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel.
Contact Dermat. 2006, 54, 348–349. [CrossRef] [PubMed]
15. Encinas, S.; Bosca, F.; Miranda, M.A. Photochemistry of 2,6-dichlorodiphenylamine and 1-chlorocarbazole,
the photoactive chromophores of diclofenac, meclofenamic acid and their major photoproducts.
Photochem. Photobiol. 1998, 68, 640–645. [CrossRef]
Molecules 2018, 23, 673 11 of 11
16. Encinas, S.; Bosca, F.; Miranda, M.A. Phototoxicity associated with diclofenac: A photophysical,
photochemical, and photobiological study on the drug and its photoproducts. Chem. Res. Toxicol. 1998, 11,
946–952. [CrossRef] [PubMed]
17. Moore, D.E.; Roberts-Thomson, S.; Zhen, D.; Duke, C.C. Photochemical studies on the antiinflammatory
drug diclofenac. Photochem. Photobiol. 1990, 52, 685–690. [CrossRef] [PubMed]
18. Ioele, G.; De Luca, M.; Tavano, L.; Ragno, G. The difficulties for a photolabile drug in topical formulations:
The case of diclofenac. Int. J. Pharm. 2014, 465, 284–290. [CrossRef] [PubMed]
19. Ioele, G.; Tavano, L.; De Luca, M.; Ragno, G.; Picci, N.; Muzzalupo, R. Photostability and ex-vivo permeation
studies on diclofenac in topical niosomal formulations. Int. J. Pharm. 2015, 494, 490–497. [CrossRef]
[PubMed]
20. Aparici-Espert, I.; Cuquerella, M.C.; Paris, C.; Lhiaubet-Vallet, V.; Miranda, M.A. Photocages for protection
and controlled release of bioactive compounds. Chem. Commun. 2016, 52, 14215–14218. [CrossRef] [PubMed]
21. Klán, P.; Šolomek, T.; Bochet, C.G.; Blanc, A.; Givens, R.; Rubina, M.; Popik, V.; Kostikov, A.; Wirz, J.
Photoremovable protecting groups in chemistry and biology: Reaction mechanisms and efficacy. Chem. Rev.
2013, 113, 119–191. [CrossRef] [PubMed]
22. Šolomek, T.; Wirz, J.; Klán, P. Searching for improved photoreleasing abilities of organic molecules.
Acc. Chem. Res. 2015, 48, 3064–3072. [CrossRef] [PubMed]
23. Young, D.D.; Deiters, A. Photochemical control of biological processes. Org. Biomol. Chem. 2007, 5, 999–1005.
[CrossRef] [PubMed]
24. Yu, H.; Li, J.; Wu, D.; Qiu, Z.; Zhang, Y. Chemistry and biological applications of photo-labile organic
molecules. Chem. Soc. Rev. 2010, 39, 464–473. [CrossRef] [PubMed]
25. Pravst, I.; Zupan, M.; Stavber, S. Solvent-free bromination of 1,3-diketones and β-keto esters with NBS.
Green Chem. 2006, 8, 1001–1005. [CrossRef]
26. Paris, C.; Lhiaubet-Vallet, V.; Jiménez, O.; Trullas, C.; Miranda, M.Á. A blocked diketo form of
avobenzone: Photostability, photosensitizing properties and triplet quenching by a triazine-derived
UVB-filter. Photochem. Photobiol. 2009, 85, 178–184. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
